AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00964847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure education/walking program
Description: The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
Study NCT03883334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metisoprinol
Description: Immunodulator
Study NCT02716701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Study NCT02716701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study NCT02716701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wristband activity tracker
Study NCT02716701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wristband activity tracker
Study NCT01881022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosexual Intervention
Description: Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
Study NCT03542851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentetrazol (PTZ)
Description: BTD-001 is an oral capsule of PTZ.
Study NCT03542851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be presented as oral capsule.
Study NCT02552251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hormonal balance measurements
Study NCT02552251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: metabolic balance measurements
Study NCT02552251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone balance measurements
Study NCT02552251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Study NCT01690351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Oral dispersion TS formulation- fasted
Study NCT00118534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care for Smoking Cessation in PTSD patients
Description: Smoking cessation therapy is integrated with PTSD therapy.
Study NCT00118534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
Study NCT01690351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Capsules TS formulation- fasted
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin (Doxorubicin)
Description: 30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adriamycin (Doxorubicin)
Description: 30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide
Description: 2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
Study NCT02005172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alivecor monitor and 14 day event monitor
Description: Alivecor monitor and 14 day event monitor
Study NCT03927287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Free PSA ratio test in patients after definitive treatment for localized prostate cancer
Description: Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: 2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
Study NCT00267046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
Study NCT04218578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: speckle tracking analysis of transthoracic echocardiogram
Description: analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
Study NCT01730157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study NCT01730157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: Given via hepatic arterial infusion
Study NCT01730157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02593292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROSPERO
Description: The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives.
Study NCT02593292 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
Study NCT03266939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: 10 mg acute administration of lorcasein
Study NCT00103142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: falimarev
Description: Given subcutaneously and intradermally
Study NCT00103142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inalimarev
Description: Given subcutaneously and intradermally
Study NCT00103142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study NCT00103142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given subcutaneously and intradermally
Study NCT03731884 — intervention group
Intervention type: OTHER
Intervention: Time from the onset of symptoms to PCI
Description: Patients will be divided in two groups according to the time from the onset of symptoms to PCI
Study NCT01396707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin+XELOX
Description: Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1
Study NCT02601742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc group
Description: Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
Study NCT02601742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Pedialyte oral electrolyte solution, 330 ml per day for 7 days
Study NCT02208947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumer financial incentive
Description: Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
Study NCT02208947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREPARE
Description: PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library).
Study NCT02208947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE
Description: PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library).
Study NCT00992082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorolac and epinephrine
Description: Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Study NCT00992082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
Study NCT02287558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT03781609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Roller system group (RG)
Description: They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
Study NCT03781609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Overground group (OG)
Description: They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
Study NCT03781609 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Wheelchair skills group (WSG)
Description: They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
Study NCT01864733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical rehabilitation (exercise).
Study NCT01864733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (exercise).
Study NCT04017585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet containing gluten
Description: gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
Study NCT04017585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Diet containing placebo
Description: Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
Study NCT03330808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
Study NCT03695562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential drilling technique
Description: Patient with vitamin D deficiency using sequential drilling technique
Study NCT03695562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sequential drilling technique
Description: Patient with vitamin D deficiency using sequential drilling technique
Study NCT00622960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Description: The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
Study NCT00622960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-CHO diet
Description: The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
Study NCT01482754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)
Description: Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
Study NCT00877877 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
Study NCT03394092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative measurements the changes of IgG glycosylation
Description: Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
Study NCT03375801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: This will be an online tool giving evidence based information and explanation on their options.
Study NCT04208204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: somatocognitive physiotherapy
Description: Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
Study NCT01358591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High calcium milk
Description: High calcium milk (9 mg/kgBM)
Study NCT01358591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Regular Milk
Study NCT05540301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sleeper stretching
Description: Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
Study NCT05540301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified cross-body adduction stretch
Description: Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
Study NCT04109755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
Study NCT04698720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation with Guided Imagery
Description: Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
Study NCT04698720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with Guided Imagery
Description: In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance.
Study NCT04698720 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Guided Imagery
Description: This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
Study NCT05735392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.
Description: Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
Study NCT00350714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBT and BreathID
Description: 75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
Study NCT04181580 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Made-to-measure compression garment
Description: Made-to-measure compression garment
Study NCT03840525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Qigong Intervention
Description: Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
Study NCT03840525 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Qigong
Description: This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
Study NCT02075632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate cream
Description: Alclometasone dipropionate cream 0.05% (15 g)